Prognostic Value of Lactate Levels in Patients With STEMI Undergoing Primary PCI

Completed

• Conditions: STEMI

• Registration Number: NCT05503329
• Lead Sponsor: Ahmed Maher Teaching Hospital

Brief Summary

To assess the prognostic value of systemic arterial lactate levels in patients with ST segment elevation myocardial infarction undergoing primary PCI and correlate with the results of primary PCI and 30 days MACE follow up.

Detailed Description

* Study Population: STEMI patients treated with primary PCI.

* Study period: over 6 months.

* Sample Size: 300 patients.

All patients received the standard care for acute STEMI patients which is the primary percutaneous intervention in addition to medications.

Hyperlactemia is defined as elevated lactic acid level in the blood. The normal blood lactate level is (0.5-1 mmol/L).

All subjects were subjected to

1. Careful history taking

2. Full cardiac examination

3. Investigations include:

1. 12 lead surface ECG.

2. Lactate level and full labs

3. Pre-discharge echocardiography

4. Peri-procedural details of primary PCI

the investigators assessed the relation between hyperlactemia and coronary flow, peak cardiac enzymes, hemodynamic parameters and MACE in 30 days follow up

Study Timeline

• Study Start: 2022-01-25
• Primary Completion: 2022-06-27
• Study Completion: 2022-06-30
• Status Verified: 2022-08
• Study First Submitted: 2022-08-14
• Study First Submitted QC: 2022-08-14
• Study First Posted: 2022-08-16
• Last Update Submitted: 2022-08-16
• Last Update Posted: 2022-08-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Patient with ST-segment elevation myocardial infarction for the first time.
• Patients undergoing primary PCI.
• Adult patients ≥ 18 years old.

Exclusion criteria:

• Hemodynamically unstable patients.
• Patients with renal impairment (creatinine clearance < 30 ml/min).
• Patients who developed flow limiting coronary dissection or mechanical complication during the procedure.
• Patients presenting > 24 hours after symptoms onset.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Major adverse caediac events	30 days	we follow up occurrence of death, reinfarction, repeated hospitalization and new onset heart failure

Trial Locations

Locations (1)

Ahmed Maher teaching hospiral; 🇪🇬 Cairo, Elsayda Zainab Square, Egypt